Stay informed with the latest litigation news. Explore now

IP Verse

Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor Agonist - EP2228064B1

EP2228064

NOVARTIS
Application Number
EP10164976A
Filing Date
May 17, 2005
Status
Granted And Under Opposition
Nov 8, 2019
Grant Date
Dec 11, 2019
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3143995B2
EP4321157B1
EP3487881B1

Bibliography

The patent EP2228064B1 was granted to Novartis on Dec 11, 2019 following the initial filing on May 17, 2005 under the application number EP10164976A . The current legal status of the patent is Granted And Under Opposition.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR SCHONSep 11, 2020ADMISSIBLE
EUROPEAN OPPOSITIONSSep 11, 2020ADMISSIBLE
HGFSep 11, 2020ADMISSIBLE
ISARPATENTSep 11, 2020ADMISSIBLE
NEDERLANDSCH OCTROOIBUREAUSep 11, 2020ADMISSIBLE
STADA ARZNEIMITTELSep 11, 2020ADMISSIBLE
ORION ORION PHARMASep 11, 2020WITHDRAWN
PGASep 10, 2020WITHDRAWN
TEVA PHARMACEUTICALSSep 8, 2020ADMISSIBLE
HOFFMANN EITLESep 8, 2020WITHDRAWN

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents